Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications

She was Group Chief Marketing Officer at CKA Birla Group in her last role

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data

Biocon Biologics collaborates with National Cancer Society Malaysia

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints

Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK

YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.